Survival of newly diagnosed patients with MM with different M-protein secretory status after receiving thalidomide- or bortezomib-based therapy. PFS and OS were remarkably extended with chemotherapy incorporating the proteasome inhibitor bortezomib in patients with measurable disease (A-B), but not in patients with unmeasurable disease (C-D).